Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab, Camrelizumab, and Utidelone in HER2+ Breast Cancer
NCT04681287Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of inetetamab, camrelizumab, utidelone in HER2-positive breast cancer, sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
inetetamabcamrelizumabutidelone
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04681287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681287.